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Abstract Vinfunine (VFL) is a novel bifluorinated
tubulin-targeted agent of the vinca alkaloids class active in
advanced stage breast cancer. We conducted a phase I
study combining VFL with doxorubicin (DXR) to define
the recommended dose (RD), safety, pharmacokinetic (PK)
interaction and efficacy. Two schedules (day 1 every
3 weeks; days 1 and 8 every 3 weeks) were investigated as
first line chemotherapy in metastatic breast cancer patients.
Thirty-two patients received a total of 162 cycles of the
VFL–DXR combination (median 6). The RDs were VFL
250 mg/m2/DXR 40 mg/m2 every 3 weeks for schedule 1
and VFL 120 mg/m2/DXR 25 mg/m2 days 1 and 8 every
3 weeks for schedule 2. The main dose-limiting toxicity
was neutropenia. The most frequent non-hematological
adverse events were nausea, fatigue, constipation, vomit-
ing, anorexia, stomatitis and dyspnea. Objective response
rate was reached in 47.1% of the patients. No PK
interaction was observed. VFL–DXR combination is fea-
sible with manageable toxicity. The antitumor activity was
promising and supports further evaluation.
Keywords Breast cancer  Advanced stage 
Vinflunine  Doxorubicin  Phase I  Pharmacokinetics
Introduction
Breast cancer (BC) is the most frequent malignancy in
women. Systemic adjuvant therapies have improved the
cure rate of the disease [1]. Nevertheless less than 10% of
the patients present with concomitant metastasis and more
than 20% with initially localized disease eventually
develop distant metastasis [2].
Although these patients cannot be cured, multiple thera-
peutic options allow the disease to be controlled for a long
time. Chemotherapy currently remains one of the cornerstones
of systemic therapy [3]. During these last decades the avail-
ability of a larger number of new drugs has led to continued
improvement in progression free survival (PFS), overall sur-
vival (OS) and quality of life of metastatic patients [4].
However median survival of the advanced stage breast cancer
(ABC) patients remains around 2–3 years. The development
of other non cross-resistant and well tolerated substances is,
therefore, one of the priorities in oncology research.
Vinflunine (VFL, Javlor, Pierre Fabre Medicament) is
a new microtubule inhibitor belonging to the family of the
vinca alkaloids [5]. It blocks cells at the G2/M cell cycle
phase and induces apoptosis. The introduction of two
fluorine atoms into the catharantine moiety has conferred
on this molecule a different and broader spectrum of
activity compared to the previous vinca alkaloids, vino-
relbine, or vinblastine. VFL inhibits tubulin assembly, but
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as a consequence of its new design it binds relatively
weakly to this structure, therefore the risk of neurotoxicity
is less than with other spindle poisons. Single agent VFL
has been shown to be clinically active in BC [6, 7], non
small cell lung cancer [8, 9] and transitional cell carcinoma
of the bladder [10]. As second and third line chemotherapy
after taxanes and anthracyclines an objective response rate
(ORR) of 13–30% and a stable disease rate of 30–35%
were observed in ABC [11].
Currently no chemotherapeutic regimen is widely
accepted as a standard in the treatment of ABC patients.
Sequential use of single agent chemotherapies may be
sufficient to treat asymptomatic patients. However combi-
nation treatments result in a higher ORR and a longer time
to disease progression [3, 12]. Multiagents treatments are
more adequate in the case of severe symptoms, rapid
progression or high tumor burden [13, 14]. Doxorubicin
(DXR) is one of the drugs most active against BC and the
reference drug in the anthracycline family. Furthermore
tumors relapsing [12 months after anthracycline-based
adjuvant treatment may still be sensitive, allowing the
reintroduction of these drugs. The mechanism of action of
DXR, as a topoisomerase II inhibitor and DNA intercalator,
is different to that of VFL supporting the hypothesis of
synergic antitumor activity. Due to the higher efficacy of
the association VFL–DXR without increased toxicity in
animal models [15], we conducted a phase I study of this
combination. We report the results of two different
schedules, weekly (day 1 and day 8 every 3 weeks) and
3-weekly, of VFL combined with DXR as first line che-
motherapy for ABC.
Patients and methods
Design
This was an open label, non-randomized, multicenter,
phase I study. A traditional 3 ? 3 dose-escalation design
was used [16]. The primary objective of the study was to
establish the recommended dose (RD) of the VFL–DXR
combination. The secondary objectives were toxicity
assessment and safety, pharmacokinetic (PK) drug-drug
interaction and antitumor activity.
The study was conducted in accordance with the Dec-
laration of Helsinki and in compliance with good clinical
and laboratory practice. Written informed consent was
obtained from each patient prior to entry into the study.
Patient selection
Inclusion criteria included women aged between 18 and
75 years, with metastatic BC, ECOG performance status of
0–2, no prior chemotherapy for ABC, more than 6 months
since the end of neo/adjuvant chemotherapy if applicable,
previous cumulative dose of DXR, epirubicin or anthra-
cenedione not exceeding 250, 450 and 72 mg/m2, respec-
tively and at least one measurable lesion according to the
Response Evaluation Criteria In Solid Tumors (RECIST)
version 1.0 [17]. Adequate biological parameters were
required: absolute neutrophil count (ANC) C2.0 9 109/l,
platelets C100 9 109/l, hemoglobin C10 g/dl, total bili-
rubin B1.5 9 upper limit of normal value (ULN), trans-
aminases B2.5 9 ULN (B5 9 ULN in the presence of
liver metastasis), creatinine B1.5 9 ULN or creatinine
clearance C50 ml/min. Exclusion criteria were: brain or
leptomeningeal metastasis; peripheral neuropathy grade C2
according to the NCI Common Toxicity Criteria version
2.0 (NCI-CTC v. 2.0); occlusive or subocclusive intestinal
disease; recent myocardial infarction (\6 months) or seri-
ous underlying cardiovascular diseases; left ventricular
ejection fraction (LVEF) \50% or any significant electro-
cardiogram abnormality; uncontrolled hypercalcaemia;
prior high-dose chemotherapy with stem cell rescue; radi-
ation therapy in the 4 weeks prior to the start of treatment;
pregnant or breast-feeding women.
Treatment regimen
VFL was given intravenously as a 20 min infusion fol-
lowed by DXR as a 30 min infusion. Antiemetics were
administered according to local standards and prophylactic
use of laxatives was recommended. Two schedules of
administration were studied (Table 1). In schedule 1 both
drugs were administered on day 1 of each 3 week cycle. In
schedule 2, they were infused on days 1 and 8 of each
3 week cycle. The dose levels are described in the Table 1.
Upfront prophylactic use of hematopoietic growth factors
(G-CSF) was not allowed during the first cycle.
Each patient received at least 2 cycles of treatment unless
there was documented disease progression, unaccept-
able toxicity, prohibitive intercurrent illness, investigator’s
decision, patient’s refusal or when the total cumulative dose
of DXR reached 550 mg/m2. After 4 cycles of treatment
continuation was allowed according to the investigator’s
discretion.
Table 1 Schedules with each dose level
Vinflunine (mg/m2) Doxorubicin (mg/m2)
Schedule 1a Level 1 250 50
Level-1 250 40
Schedule 2b Level 1 150 25
Level-1 120 25
a Day 1 every 3 weeks
b Day 1 and 8 every 3 weeks
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Treatment modifications: on day 1, treatment was
delayed for 1 week if ANC \1.5 9 109/l or platelets
\100 9 109/l; in schedule 2 only, on day 8, one dose level
reduction was required if ANC 0.5–1.0 9 109/l or platelets
50–100 9 109/l. The treatment was delayed if ANC or
platelets were less than 0.5 and 50 9 109/l, respectively.
In the event of febrile neutropenia (FN), grade 4 throm-
bocytopenia or grade 4 neutropenia for C7 days, doses
were reduced to the next lower level. A maximum of two
dose reductions was allowed. In case of organ toxicity
[grade 2, treatment on day 1 was delayed by 1 week and
treatment on day 8 (schedule 2 only) was cancelled. The
doses of the next cycle were decreased by 1 level in case of
grade 2 mucositis and constipation for more than 5 days or
any grade C3 toxicity. In case of[2 week delay because of
any toxicity, the patient was withdrawn from the study.
Assessments
Baseline examinations included: medical history, physical
examination, ECOG performance status, electrocardiogram
(EKG), LVEF assessment, complete blood cell count,
biochemistry measurements, and tumor assessment by
bone scan, CT scan and/or MRI. Medical history, clinical
examination, blood tests and EKG were repeated on day 1
of each cycle. LVEF and tumor assessment were repeated
every 2 cycles. Complete blood cell count was measured at
least on days 1, 3, 8 and 15 and every 2 days when ANC
was \0.5 9 109/l. After completion of the study, the
patients were followed lifelong every 3 months.
Safety was assessed according to the NCI-CTC v. 2.0.
Dose limiting toxicity (DLT) was defined as any of the
following adverse events occurring during the first cycle:
non-hematological toxicity grade C3 (except alopecia and
inadequately premedicated nausea/vomiting); neutropenia
\0.5 9 109/l for C7 days or \0.1 9 109/l for C3 days;
platelets \25 9 109/l or thrombocytopenia with bleeding
or requiring platelets transfusion; FN. The recommended
dose (RD) was defined as the dose level immediately below
the maximum tolerated dose (MTD) resulting from a DLT
with at least 6 patients treated at the RD.
Efficacy was determined by the response rate according
to the RECIST v. 1.0 [17] in all patients having received at
least 2 cycles of treatment.
Pharmacokinetics (PK)
Eleven blood samples were collected from pre-dose to
168 h after VFL administration on day 1 for schedule 1 and
on day 8 for schedule 2. Drug concentrations were
Table 2 Patients’
characteristics
Schedule 1 n = 15 Schedule 2 n = 17
Median age (range) 56.0 years (44.2–74.6) 59.9 years (48.8–73.9)
Performance status (%)
0–1 93.3 88.2
2 6.7 11.8
Histological type (%)
Ductal 60 70.6
Lobular 26.7 17.6
Others 13.3 11.8
Tumor initial grade (%)
1 6.7 11.8
2–3 80.0 64.7
Unknown 13.3 23.6
Median disease free interval (%)
C 2 years 46.7 70.6
\ 2 years 53.3 29.4
Number of organs involved (%)
1 26.7 17.6
C 2 73.3 82.4
Visceral involvement (%) 80.0 82.4
Prior surgery (%) 80.0 88.2
Prior radiotherapy (%) 53.3 88.2
Prior endocrine therapy (%) 40.0 76.5
Prior chemotherapy (%) 26.7 23.5
Anthracyclines 20.0 23.5
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measured in centralized bioanalytical laboratories: VFL
and its active metabolite 4-O-deacetylvinflunine (DVFL)
were assayed in whole blood. DXR and its active metab-
olite doxorubicinol were assayed in plasma. The PK
analysis involved a graphical approach based on drug
concentration results, and the calculation of PK parameters
using a population PK model for VFL [18], and using a
noncompartmental method for DXR and doxorubicinol.
Potential impact of DXR on the PK of VFL was
assessed by comparing Bayesian values of total blood
clearance (Cltot) with those of a reference dataset made up
of 3 Phase I dose escalating studies with VFL mono-
therapy. Conversely, a potential impact of VFL on the PK
of DXR and doxorubicinol were assessed by comparing
their PK parameters to published data on DXR adminis-
tered as a single agent.
Results
Recommended dose, tolerability and safety (Table 3)
Schedule 1
Fifteen patients (Table 2) received a total of 73 cycles with
a median of 6 and a range of 1–8 cycles. The median
relative dose intensities of VFL and DXR were 99.2%
[92.6–100.8] and 98.8% [76.7–103.7], respectively.
At dose level 1, two of the 6 evaluable patients expe-
rienced a DLT (2 patients were not evaluable for MTD
because of inadequate blood monitoring): one neutropenia
\0.1 9 109/l for C3 days and one episode of neutropenic
infection. This level was identified as the MTD. At dose
level-1 seven patients were included and no DLT was
observed, therefore the RD was established as VFL
250 mg/m2 and DXR 40 mg/m2 on day 1 every 3 weeks.
The most frequently reported hematological toxicity was
neutropenia. Grade 3 occurred in 1 patient (6.7%) and
grade 4 in 11 patients (73.3%) and 43.8% of cycles At
MTD the 8 patients treated (100.0%) developed grade 4
neutropenia. Among them, 2 episodes of FN were reported
in 2 patients (25.0%) and 2 episodes of neutropenic
infection in 2 patients (25.0%). At RD 4 out of 7 patients
(57.2%) developed severe neutropenia, one grade 3 and
three grade 4. Two cases of grade 3 anemia were observed
at MTD and none at RD. Three patients experienced grade
3 thrombocytopenia at the MTD and none at the RD.
The main non-hematological adverse events related to
study treatment were gastrointestinal disorders: nausea in 12
patients (80.0%), constipation and vomiting in 6 patients each
(40.0%), stomatitis and abdominal pain in 3 patients each
(20.0%); general disorder: fatigue in 11 patients (73.3%);
skin disorder: alopecia in 10 patients (66.7%); and
nutritional disorder: anorexia in 5 patients (33.3%). Study
drug related cardiac toxicities included asymptomatic
decrease in LVEF (grade 1 and 2) experienced by four
patients (26.7%), 3 at MTD and 1 at RD and a grade 1
diastolic dysfunction in one patient at MTD. One case of
cardiomyopathy was observed 2 months after the end of the
study treatment and improved after corrective treatment. No
treatment related death occurred. In general overall toxicity
was manageable, especially at the RD, where hematological
toxicity was moderate and reversible. At RD, no grade 3/4
non-hematological toxicity was observed except in 1 patient
who suffered grade 3 fatigue. In total, two out of the 15
patients in schedule 1 discontinued the treatment because of
a study drug-related adverse event after 2 and 4 cycles,
respectively, both patients were at MTD.
Schedule 2
Seventeen patients received a total of 89 cycles with a
median of 6 and a range of 1–8 cycles. Median relative
dose intensities of VFL and DXR were 75.0% [38.3–115.7]
and 77.3% [36.7–92.5], respectively.
At dose level 1, 2 out of 4 evaluable patients experi-
enced at least one DLT (5 patients were not evaluable for
MTD determination, because of missing information on
blood cell count tests) : neutrophils \0.5 9 109/l for
C7 days, neutropenic infection, grade 3 constipation and
arm deep venous thrombosis. This level was defined as the
MTD. At dose level-1, eight patients were included and
one DLT (ANC\0.5 g/l for C7 days) was observed out of
the 6 evaluable patients, therefore the RD was established
as VFL 120 mg/m2 and DXR 25 mg/m2 on day 1 and day 8
every 3 weeks.
The major hematological toxicity was neutropenia.
Grade 3 occurred in 2 patients (11.8%) and grade 4 in 12
patients (70.6%) and 41.6% of cycles. At MTD, 8 out of
the 9 patients treated (88.9%) developed grade 4 neutro-
penia. Among them, one episode of FN was reported in one
patient (12.5%) and 4 episodes of neutropenic infection in
4 patients (50.0%) all at MTD. At RD, 7 out of the 8
patients (87.5%) developed neutropenia, one grade 3
(12.5%) and four grade 4 (50.0%). One grade 3 anemia was
observed at MTD and none at RD. Two cases of grade 3
thrombocytopenia occurred, 1 at MTD and 1 at RD.
The main non-hematological adverse events related to
study treatments were gastrointestinal disorders: constipa-
tion and nausea in 13 patients each (76.5%), vomiting in 11
patients (64.7%), stomatitis in 7 patients (41.2%), diarrhea
and abdominal pain in 4 patients each (23.5%); general
disorder: fatigue in 14 patients (82.4%); nutritional disorder:
anorexia in 6 patients (35.3%). Two grade 3 fatigue, one
grade 3 constipation, one grade 3 vomiting and three grade 3
vein thrombosis were reported and occurred at MTD,
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while no non-hematological grade 3/4 toxicity was observed
at RD. Study drug related cardiac toxicities included grade 1
palpitations in 2 patients (one at MTD and one at RD) and a
grade 1 tachycardia in one patient at MTD. Asymptomatic
LVEF decrease was observed in 1 patient at RD, not related
to the study drugs according to the investigator. One death
occurred within 30 days after last study drug administration
but according to the investigator was not related to the study
treatment. In total, overall toxicity was manageable and the
hematological toxicity was reversible. In total, for schedule
2, one patient out of 17, treated at MTD, discontinued the
treatment because of a study drug-related adverse event after
4 cycles (fatigue grade 3).
Antitumor activity assessment
Tumor best response in the ITT population is reported in
the Table 4. In schedule 1, 7 patients reached an objective
response (46.7%) according to the investigator’s assess-
ment. In the evaluable population 6 objective responses
were reported (46.2%). The best overall response was
partial response. In schedule 2, 8 patients presented an
objective response (47.1%). In the evaluable population 8
objective responses were reported (53.3%).
Pharmacokinetics
Schedule 1
Fifteen patients were evaluable for DXR and doxorubi-
cinol, and 14 patients for VFL and DVFL PK. For VFL,
a difference in mean Cltot values was suggested between
the 2 dose levels of DXR (40 and 50 mg/m2). This dif-
ference was not confirmed as all the individual values were
fully overlapped by the Phase I monotherapy dataset values
(Fig. 1). For DVFL, no modifications of blood concentra-
tions were observed when compared to the dose-adjusted
reference values.
PK parameters of DXR and doxorubicinol were not
modified by VFL, as their values were consistent with the
published data on DXR administered as a single agent [19].
For doxorubicinol the mean terminal half-life was also in
line with published data [20].
Schedule 2
For VFL and DXR, a total of 15 out of 17 patients enrolled
were evaluable for PK assessment. For VFL, a slight dif-
ference in mean Cltot values was suggested between the 2
dose levels of VFL (120 and 150 mg/m2). Similarly as for
schedule 1, the graphical analysis showed a full overlap
between all the individual VFL clearance values compared
to the reference dataset (Fig. 2). No modification was
detected for DVFL and DXR/doxorubicinol, similarly as
described above for schedule 1.
Discussion
The objective of this phase I study was to establish the
recommended dose of VFL administered in combination
with DXR. No dose escalation could be performed as the
Table 3 Hematological and
non-hematological grade 3 and
4 toxicities
Schedule 1 Schedule 2
Level 1 n (%) Level-1 n (%) Level 1 n (%) Level-1 n (%)
G3 G4 G3 G4 G3 G4 G3 G4
Hematological
Anemia 2 (25.0) 1 (11.1)
Febrile neutropenia 2 (25.0) 1 (11.1)
Neutropenia 8 (100.0) 1 (14.3) 3 (42.9) 1 (11.1) 8 (88.9) 1 (12.5) 4 (50.0)
Thrombocytopenia 3 (37.5) 1 (11.1) 1 (12.5)
Non-hematological
Vomiting 1 (11.1)
Constipation 1 (11.1)
Stomatitis 1 (12.5)
Colitis 1 (12.5)
Fatigue 2 (25.0) 1 (14.3) 2 (22.2)
Anorexia 1 (12.5)
Neuropathic pain 1 (12.5)
Arthralgia 1 (12.5)
Deep vein thrombosis 3 (33.3)
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starting dose level 1 was established as the MTD. The dose
limiting toxicity was neutropenia in these patients who
were not receiving G-CSF as primary prophylaxis. Dividing
the doses of both study drugs into two doses administered
on days 1 and 8 of every 3-week cycle (schedule 2) did not
improve the hematological toxicity.
The incidence of neutropenia was similar in both
schedules, but a higher rate of complications was reported
for schedule 2 (cycle delay, dose reduction, growth factor
administration and neutropenic infection). The final rec-
ommended schedule was therefore defined as VFL 250 mg/m2
and DXR 40 mg/m2 on day 1 every 3 weeks.
Combination chemotherapy regimens improve antitu-
mor response to the treatment compared to monotherapies,
but increase adverse events, especially neutropenia [12].
Indeed, the association of docetaxel 75 mg/m2 and DXR
50 mg/m2 resulted in 97% of grade 3/4 neutropenia and
33% of FN [21]. Other well known combinations such as
gemcitabine–docetaxel, capecitabine–docetaxel [22] or
ixabepilone–capecitabine [23] showed, respectively 84, 79
and 68% grade 3 and 4 neutropenia.
The most frequent non-hematological adverse events
were fatigue, constipation, nausea, vomiting, stomatitis and
loss of appetite. At the RD, they were all mild or moderate
Table 4 Treatment efficacy
(best response) in ITT
population
Schedule 1 n = 15 Schedule 2 n = 17
Level 1
n = 8 (%)
Level-1
n = 7 (%)
Level 1
n = 9 (%)
Level-1
n = 8 (%)
Partial response 4 (50.0) 3 (42.9) 5 (55.6) 3 (37.5)
Stable disease 1 (12.5) 3 (42.9) 3 (33.3) 3 (37.5)
Progressive disease 2 (25.0) 1 (14.3) 1 (11.1) 1 (12.5)
Not evaluable 1 (12.5) 0 0 1 (12.5)
35.7 (7.5)
47.7 (12.0)
42.3 (10.2)
0
10
20
30
40
50
60
70
80
ref phase I 
(N=79 pts) VFL 250 mg/m²/ DXR 40 mg/m²(N=6)
VFL 250 mg/m²/ DXR 50 mg/m²
(N=8)
VF
L 
CL
to
t (L
/h)
Individual values
Mean (SD)
Fig. 1 Individual Cltot of
vinflunine compared between
dose levels and with reference
dataset—Schedule 1
40.8 (8.1)
35.6 (5.5)
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Mean (SD)
Fig. 2 Individual Cltot of
vinflunine compared between
dose levels and with the ref.
dataset—Schedule 2
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(grade 1 or 2), except for one patient who presented a grade
3 fatigue. No treatment discontinuation was related to the
study treatment at the RD. Constipation is an issue when
patients are treated with VFL [11], but the prophylactic use
of laxatives efficiently prevents this inconvenience in most
patients. Concerning peripheral neuropathy, which is
known to be related to the spindle poisons, no grade 3 or 4
adverse event was reported. The systematic follow up of
cardiac function showed a good safety profile of the
combination in this population of patients where about
20% were pretreated with anthracyclines.
As common metabolic and elimination pathways were
identified for both drugs [24, 25] a PK drug–drug interac-
tion might have been suspected. In this combination study,
no PK interaction was evidenced, as clearance values and/or
circulating concentrations of VFL, DXR and their active
metabolites were consistent with reference data of each
drug administered as monotherapy. Thus the tolerance
profile of the combination should only be analyzed from a
pharmacodynamic point of view rather than from a PK
interaction between both substances.
About 80% of the patients had visceral metastasis and
C2 organs were involved in 73–82% (Table 2). The ORR
were 46.7% in schedule 1 and 47.1% in schedule 2. Thus
despite the unfeasibility of dose escalation, the antitumor
activity of the combination of VFL–DXR was promising
compared to those of the other usual combinations. The
phase III study comparing gemcitabine plus docetaxel to
capecitabine plus docetaxel showed ORR of 43 and 29%
in the first-line population [22]. Ixabepilone associated
with capecitabine achieved an ORR of 42% [23]. The
interim results of liposomal DXR associated with doce-
taxel showed an ORR of 35% [26]. Finally paclitaxel
with bevacizumab reached an ORR of 36.9% in the
E2100 trial [27]. Thus even if the direct comparison of
the ORR between these different studies is arguable
because of differences in population selection, the anti-
tumor activity of VFL with DXR appears interesting.
Other studies assessing VFL alone or in association with
gemcitabine, capecitabine and trastuzumab are ongoing in
ABC.
In conclusion, the combination of VFL and DXR
administered day 1 every 3 weeks is feasible and demon-
strates an encouraging anti-tumor activity with manageable
adverse events. With the smaller size of the primary tumors
thanks to screening mammography and the efforts to avoid
chemotherapy in patients with early stage endocrine sen-
sitive tumors [28, 29], adjuvant chemotherapy will proba-
bly be used less frequently in the future. On the other hand
non anthracycline chemotherapy regimens are increasingly
used in the adjuvant setting [30–32]. Therefore the
administration of an anthracycline combination is a valu-
able and interesting option in the metastatic setting. Further
studies are needed to confirm the benefit of the new
combination of VFL and DXR.
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